Actinium Pharmaceuticals/ATNM

$8.47

-0.7%
-
1D1W1MYTD1YMAX

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. The Company develops and markets medicines for relapsed or refractory cancer patients who are treated primarily in large quaternary care hospitals and their catchment areas. Its Iomab-B and Actimab-A product candidates fill the major unmet medical needs in relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B is a targeted bridging therapy that provides both disease control and conditioning in one agent. Actimab-A is a targeted therapy for fit patients that has demonstrated an impressive extension in survival in a proof-of-concept study and is poised for advanced development in collaboration with the National Cancer Institute (NCI).

Ticker

ATNM

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

CEO

Sandesh Seth

Employees

49

Headquarters

New york, United States

ATNM Metrics

BasicAdvanced
$232.19M
Market cap
-
P/E ratio
-$1.92
EPS
0.02
Beta
-
Dividend rate

What the Analysts think about ATNM

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
180.99% upside
High $50.00
Low $9.80
$8.47
Current price
$23.80
Average price target

ATNM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-13.2M
-12.58%
Profit margin
0%
-

ATNM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.84%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.43
-$0.43
-$0.58
-$0.49
-
Expected
-$0.36
-$0.42
-$0.48
-$0.53
-$0.54
Surprise
21.13%
1.57%
20.83%
-7.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Actinium Pharmaceuticals stock

Buy or sell Actinium Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing